News
Germany’s Merck KGaA has presented detailed results from cohort B of the global Phase II WILLOW study of enpatoran, an ...
German science and technology firm Merck KGaA (MRK: DE) has moved a step closer to introducing a new therapy for tenosynovial ...
New findings suggest that a PSA level of 0.2 ng/mL or greater can predict a poor prognosis and indicate a possible need for ...
THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in U.S. infants. The U.S. Food ...
Learn more about the effects US pharmaceutical tariffs could have on European companies and their strategies for overcoming ...
In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...
The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors with one complete response, one long-lasting partial response, and 11 pati ...
The protests are a widespread rebuke of Trump’s immigration policies. The president won the election on a pledge to conduct mass deportations, and he has used cinematic raids to signal he’s making ...
BIOSeedin Innovation Partnering Conference solidified its role as a nexus for global biopharma innovation, attracting more than 2,000 registrants from 10 countries. Senior executives and investors ...
As of 1:13:21 PM GMT+2. Market Open.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results